Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / Visus Therapeutics Inc.
Entity

Visus Therapeutics Inc.

Tracked across 1 events · 12 articles · First seen Aug 20, 2026 · Last active Aug 21, 2026

Sentiment
25
Attention
2
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
2 25
Business
Lupin VISUfarma licenses YUVEZZI in Europe
Lupin (company)'s wholly-owned subsidiary VISUfarma has entered into an exclusive licensing agreement with Visus Therapeutics Inc., a wholly-owned subsidiary of Tenpoint Therapeutics Holding Limited, to commercialize YUVEZZI, a once-daily eye drop for presbyopia, in the…
Impact: Visus, the licensor, receives a strategic investment and potential milestone payments, providing funding and validation for YUVEZZI. The partnership expands the product's reach into European Union — Europe, complementing its U.S. commercialization efforts.
Aug 20, 2026 · 12 articles
Key Actions (3)
100 VISUfarma signed exclusive licensing agreement Visus Therapeutics Inc.Lupin VISUfarma licenses...
90 Lupin (company) entered licensing agreement Visus Therapeutics Inc.Lupin VISUfarma licenses...
80 VISUfarma will make strategic investment Visus Therapeutics Inc.Lupin VISUfarma licenses...
ERGEN INTELLIGENCE
Track Visus Therapeutics Inc. live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.